DE69830156D1 - Zusammensetzungen zur immunverstärkung von impfstoffen - Google Patents

Zusammensetzungen zur immunverstärkung von impfstoffen

Info

Publication number
DE69830156D1
DE69830156D1 DE69830156T DE69830156T DE69830156D1 DE 69830156 D1 DE69830156 D1 DE 69830156D1 DE 69830156 T DE69830156 T DE 69830156T DE 69830156 T DE69830156 T DE 69830156T DE 69830156 D1 DE69830156 D1 DE 69830156D1
Authority
DE
Germany
Prior art keywords
vaccines
compositions
immune improvement
immune
improvement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69830156T
Other languages
English (en)
Other versions
DE69830156T2 (de
Inventor
Rubido Julio Cesar Aguilar
Gonzalez Verena Lucila Muzio
Angulo Maria De Jes S Leal
Nieto Gerardo Enrique Guillen
Arias Eduardo Penton
Rios Gloria Veliz
Diaz Dagmara Pichardo
Buch Antonieta Herrera
Perez Enrique Iglesias
Ricondo Luis Javier Cruz
Portilla Tania Carmenate
Pardillo Cirse Mesa
Gay Maydel Hechavarria
Martinez Maylin Diaz
Pinol Juan Joel Madrazo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of DE69830156D1 publication Critical patent/DE69830156D1/de
Application granted granted Critical
Publication of DE69830156T2 publication Critical patent/DE69830156T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69830156T 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen Expired - Fee Related DE69830156T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal
CU2797 1997-03-06
PCT/CU1998/000003 WO1998039032A1 (es) 1997-03-06 1998-03-05 Formulaciones inmunopotenciadoras para uso vacunal

Publications (2)

Publication Number Publication Date
DE69830156D1 true DE69830156D1 (de) 2005-06-16
DE69830156T2 DE69830156T2 (de) 2006-01-26

Family

ID=5459228

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830156T Expired - Fee Related DE69830156T2 (de) 1997-03-06 1998-03-05 Zusammensetzungen zur immunverstärkung von impfstoffen

Country Status (15)

Country Link
US (1) US6355414B1 (de)
EP (1) EP0971737B1 (de)
CN (1) CN1161154C (de)
AR (1) AR009866A1 (de)
AT (1) ATE295182T1 (de)
AU (1) AU6607798A (de)
BR (1) BR9808832A (de)
CA (1) CA2283344A1 (de)
CU (1) CU22629A1 (de)
DE (1) DE69830156T2 (de)
ES (1) ES2241122T3 (de)
HK (1) HK1026626A1 (de)
MY (1) MY132817A (de)
WO (1) WO1998039032A1 (de)
ZA (1) ZA981897B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
WO2006055711A1 (en) * 2004-11-18 2006-05-26 Kent Hann Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
EA200800917A1 (ru) 2005-04-25 2008-12-30 Бакулиш Мафатлал Хамар Адъюванты для вакцин
US20080220028A1 (en) 2006-12-15 2008-09-11 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
EP0418626B1 (de) * 1989-09-08 1993-12-29 Takeda Chemical Industries, Ltd. Fusionsproteine und Herstellung davon
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
CZ283910B6 (cs) * 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JPH08183742A (ja) * 1994-12-28 1996-07-16 Dai Ichi Seiyaku Co Ltd 経鼻ワクチンリポソーム
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
CN1252002A (zh) 2000-05-03
WO1998039032A1 (es) 1998-09-11
BR9808832A (pt) 2000-07-04
CA2283344A1 (en) 1998-09-11
ES2241122T3 (es) 2005-10-16
AR009866A1 (es) 2000-05-03
CN1161154C (zh) 2004-08-11
HK1026626A1 (en) 2000-12-22
EP0971737A1 (de) 2000-01-19
AU6607798A (en) 1998-09-22
ATE295182T1 (de) 2005-05-15
CU22629A1 (es) 2000-12-22
EP0971737B1 (de) 2005-05-11
US6355414B1 (en) 2002-03-12
ZA981897B (en) 1998-09-07
MY132817A (en) 2007-10-31
DE69830156T2 (de) 2006-01-26

Similar Documents

Publication Publication Date Title
HUP0103908A3 (en) Novel infulenza virus vaccine composition
NO20003303L (no) Vaksine
IS5375A (is) KAY-nýstárlegt ónæmisprótín
DE69730839D1 (de) Hühner polynukleotide impfstoff-formulierung
NO20004758L (no) Vaksinesammensetning
ATE239011T1 (de) Neuartige form von s-omeprazol
DE69833516D1 (de) Verfahren zur Herstellung von Vanillin
DE69817072D1 (de) Verfahren zur Herstellung von Polysiloxan-Copolymeren
DE69830437D1 (de) Herstellung von tertiären Aminoxiden
DE69723576D1 (de) Die eierschalen von geflügel stärkende zusammensetzung
DE69909208D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE59702654D1 (de) Verfahren zur Herstellung von Methylchlorsilanen
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE69822559D1 (de) Siliconzusammensetzung
DE59713017D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE69708032D1 (de) Verfahren zur Herstellung von Trimethylcatecholdiestern
DE69806876T2 (de) Verfahren zur Herstellung von 2-Chlorprop-1-en
DE69907295D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE69930733D1 (de) Herstellung von substituierten (amino)alkoxysilanen
DE69826915D1 (de) Verfahren zur Herstellung von 3-Methyltetrahydrofuran
DE59802385D1 (de) Verfahren zur Herstellung von N-Alkylcarbazolen
DE69830351D1 (de) Verfahren zur Herstellung von Siloxanzusammensetzungen
DE69807409D1 (de) Verfahren zur Herstellung von 7-Octen-1-al
DE69834325D1 (de) Verfahren zur herstellung von cyclischen oligosiloxanen
DE69801350D1 (de) Verfahren zur Herstellung von Diacetoxybuten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee